Conference Coverage
Conference Coverage
Causal AI quantifies CV risk, providing patient-specific goals
Causal artificial intelligence is showing how specific risk factors can be overcome to avoid cardiovascular events.
Conference Coverage
NUDGE-FLU: Electronic ‘nudges’ boost flu shot uptake in seniors
Two strategies based on electronically delivered letters or “nudges” were found to increase flu shot uptake, compared with usual care, a new study...
Conference Coverage
Bempedoic acid cuts CV events in statin-intolerant patients: CLEAR Outcomes
The CLEAR Outcomes trial establishes this new drug as an important addition to available nonstatin LDL cholesterol–lowering therapies, experts say...
Conference Coverage
500 more steps a day tied to 14% lower CVD risk in older adults
New study supports the value of modest but consistent activity to improve heart health.
Conference Coverage
Old drug verapamil may have new use in type 1 diabetes
In randomized trial, the old cardiac agent slowed the destruction of insulin-producing beta cells in youth with new-onset type 1 diabetes.
Conference Coverage
Insomnia, short sleep linked to greater risk for MI
Health care professionals should be asking all patients about their sleep as a key aspect of maintaining heart health, says a sleep expert.
Conference Coverage
Therapy app cut A1c, drug intensification in T2D
Conference Coverage
Metformin linked to reductions in COVID-19 viral load
Key questions the findings raise include whether the results correlate with clinical outcomes or transmission, and whether the findings are...
Conference Coverage
Rucaparib benefit in BRCA+ prostate cancer confirmed
New study finding provides evidence of clinical benefit for an indication for rucaparib that was granted an accelerated approval in May 2020.
Conference Coverage
A starting point for precision medicine in type 1 diabetes
New evidence about the epidemiology, genetics, and possible constituent causes of type 1 diabetes is offering clues to precision medicine for this...
Conference Coverage
Black HFrEF patients get more empagliflozin benefit in EMPEROR analyses
Empagliflozin trial data in patients with heart failure with reduced ejection fraction signal more benefit in Black, compared with White patients...